Roth Capital maintained a Buy rating on Cempra, Inc. (NASDAQ: CEMP), and cut the price target to $40.00 (from $56.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Baird Remains Bullish as Market Reacts to Cempra's (CEMP) 2nd Phase 3 Study of Solithromycin October 19, 2015 10:17 AM Cempra to Report Third Quarter 2015 Financial ResultsOctober 19, 2015 8:02 AM Cempra to Report Third Quarter 2015 Financial ResultsOctober 19, 2015 8:01 AM SOLITAIRE-IV Data Not as Strong as ORAL; Leerink Partners Cuts Price Target on Cempra's (CEMP) to $21 October 16, 2015 1:13 PM Unusual 11 Mid-Day Movers 10/16: (YOKU) (SFXE) (YGE) Higher; (ZFGN) (CEMP) (PWR) LowerOctober 16, 2015 12:54 PM Pre-Open Stock Movers 10/16: (SFXE) (YOKU) (BOX) Higher; (ZFGN) (CEMP) (WYNN) LowerOctober 16, 2015 9:39 AM Cempra (CEMP) Announces Solitaire-IV Met All Endpoints in Phase 3October 16, 2015 7:01 AM Cempra Announces Positive Topline Phase 3 Clinical Results for Intravenous Solithromycin in the Treatment of Community-Acquired Bacterial PneumoniaOctober 16, 2015 7:00 AM Cempra Announces Positive Topline Phase 3 Clinical Results for Intravenous Solithromycin in the Treatment of Community-Acquired Bacterial PneumoniaOctober 16, 2015 7:00 AM